Children's National - NIAID Partnership

Protocol Title: Investigating the Mechanistic Biology of Immunodeficiency Disorders

Status: Recruiting

Project contact person: Stephanie Norman, [email protected]

This study investigates novel forms of primary immunodeficiency (PID) and to better define the natural history of both new and previously described forms of PID, including severe combined immunodeficiency (SCID), combined immunodeficiency, natural killer (NK) cell deficiency, and other disorders. Patients with clinical and/or laboratory evidence of PID will be recruited at Children's National and NIAID, and will provide one or more blood donations during the course of the study to enable immunologic and genetic investigations of immune pathways contributing to PIDs. These subjects will also be followed clinically to longitudinally assess the natural history of novel and known PIDs. Subjects will be followed over time with regard to their immunologic phenotype, clinical disease (including incidence of infections, autoimmune phenomena, allergic disease, or malignancies), and response to both preventative and definitive therapies. Biological relatives who do not have PID and healthy adult volunteers will also be eligible to serve as controls for this study.

Children's National

Michael Keller, M.D., is a pediatric immunologist at Children's National Hospital and specializes in the diagnosis and treatment of primary and secondary immunodeficiency disorders. He has authored many peer-reviewed articles and contributed to expert consensus guidelines on the treatment and diagnosis of primary immunodeficiency disorders. Dr. Keller is a member of the American Academy of Allergy, Asthma, and Immunology (AAAAI); the Clinical Immunology Society; the European Society of Immunodeficiency; and the Primary Immunodeficiency Treatment Consortium (PIDTC).

Dr. Keller's research focuses on the use of adoptive T-cell therapies for treatment of infections in immunocompromised patients, including the use of this therapy to improve outcomes in children with primary immunodeficiency disorders as well as those undergoing bone marrow transplantation for cancer. He is the primary investigator of several Phase I-II studies of virus-specific T-cell immunotherapy.

NIAID

Luigi D. Notarangelo, M.D., received his medical degree from the University of Pavia, Italy. After completing training in pediatrics, subspecialty training in allergy/immunology, and human genetics at the University of Pavia and a postdoctoral internship with David Nelson, M.D., at the Metabolism Branch, National Cancer Institute, he was appointed associate professor and subsequently full professor of pediatrics at the University of Brescia, Italy, where he chaired the department of pediatrics between 2000 and 2006. In November 2006, he joined the division of immunology at Boston Children’s Hospital, Harvard Medical School, as professor of pediatrics. In October 2016, he joined the Laboratory of Host Defenses.

Dr. Notarangelo is a leader in the study of the molecular and cellular mechanisms of human primary immune deficiencies and in the treatment of these disorders. He has served as president of the European Society for Immune Deficiencies and of the Clinical Immunology Society. He has received numerous national and international awards.

Ottavia Delmonte, M.D., is the Assistant Research Physician of the Clinical Immunology and Microbiology Laboratory at NIAID.

Protocol Title: Natural History and Mechanistic Investigation of Atopic Disease in Childhood

Status: Recruiting.

Project contact person: Stephanie Norman, [email protected]

The prevalence of atopic diseases has increased both in developed and developing countries in recent decades. Atopic diseases typically manifest in early childhood, progress through the first decade of life through what has become known as the ‘atopic march’ and then often persist throughout one’s lifetime. This study will investigate the natural history of atopic diseases, including food allergies and asthma, to better understand the risk factors, predictors, and mechanisms underlying these diseases. Samples will be collected from patients with some form of atopic disease as well as healthy controls, for ex vivo analysis and in vitro experiments.

Children's National

Hemant Sharma, M.D., M.H.S., is the Chief of the Division of Allergy and Immunology at Children’s National. He is an Associate Professor of Pediatrics at George Washington University School of Medicine, and the Director of the Food Allergy Program at Children’s National. He has served as the site director of the allergy immunology fellowship program with the National Institutes of Health. He is Director of the FARE (Food Allergy Research & Education) Clinical Network site at Children’s National.

He joined the faculty at Children’s National in 2008. His areas of clinical, advocacy and research interest include racial and socioeconomic health disparities and community-based management of food allergy. He writes a quarterly column in Allergic Living magazine and answers readers’ food allergy questions. He is heavily involved in advocacy, participating in regional and national legislative efforts to improve the health of the food allergy community. Dr. Sharma is board-certified in Pediatrics and in Allergy and Immunology, and is a fellow of the American Academy of Allergy, Asthma and Immunology, serving on the Adverse Reactions to Foods Committee. Due to his efforts on behalf of the food allergy community, he was selected to receive the 2016 FARE Vision Award.

William Sheehan, M.D., is a board-certified allergist and immunologist. He earned his medical degree from the Northwestern University Feinberg School of Medicine and a Bachelor of Arts degree from the College of the Holy Cross. Dr. Sheehan completed pediatrics internship and residency programs at the Duke University Medical Center before joining the Children’s Hospital of Boston Fellowship Program in Allergy and Immunology. He joined Children’s National Hospital in August 2017.

Dr. Sheehan finds joy in helping patients with asthma, allergies, eczema and immunodeficiency. When not seeing patients, he is active in clinical research on asthma and allergies. He has spent much of his career investigating the interaction of environmental exposures and asthma. Dr. Sheehan's work has focused on improving the lives of inner-city children by eliminating detrimental exposure and improving health outcomes. With his expertise, he has assisted on several multi-center national asthma research networks. Additionally, Dr. Sheehan has recently been involved in two groundbreaking asthma prevention trials.

Pamela Guerrerio, M.D., Ph.D., graduated with a B.S. degree in biology from the University of Iowa and entered the Medical Scientist Training Program at Johns Hopkins University, where she completed medical school and a Ph.D. in human genetics. She also did her residency in pediatrics and fellowship in allergy and immunology at Johns Hopkins, and subsequently joined the faculty. In 2014, Dr. Guerrerio was recruited to the NIAID intramural research program as Chief of the Food Allergy Research Unit. She received tenure in 2019 and was named Chief of the Laboratory of Allergic Diseases in 2020. Dr. Guerrerio was the recipient of the ARTrust Faculty Development Award from the American Academy of Asthma, Allergy and Immunology in 2011. She received the Presidential Early Career Award for Scientists and Engineers, the National Science Foundation’s highest honor for science and engineering professionals in the early stages of their independent research career, in 2017.

Protocol Title: Characterization of Pediatric Lyme Disease: Clinical Manifestations, Long Term Outcome, Immune Response, and Prevalence of PTLDs

Status: Substudy 1 - completed. Substudy 2 – not yet recruiting.

Project contact person: Stephanie Norman, [email protected]

The protocol proposes two paired substudies designed to characterize the clinical manifestations and long-term outcomes among pediatric Lyme disease patients in the greater Washington, DC area. Substudy 1 will characterize the natural history and longterm clinical, quality of life, and cognitive outcome of pediatric patients diagnosed with early and late stage Lyme disease, including prevalence of Post-Treatment Lyme Syndrome (PTLDS) and Substudy 2 will compare clinical, behavioral, cognitive and(future) immunologic response profiles between patients with full recovery, PTLDS and healthy controls. We will assess timeframe for resolution of symptoms after appropriate treatment, estimate the prevalence of PTLDS among a diverse cohort of pediatric patients diagnosed with Lyme disease within the past decade, and obtain specimens for future studies to identify the immune response of patients with PTLDS compared to patients who fully recovered from Lyme disease and healthy controls, as well as recently diagnosed patients with different manifestations of Lyme disease (early localized, disseminated, and late disease). Results of these analyses will be used to identify profiles and biomarkers that correlate with the outcome phenotypes. This signature could allow the design of a prognostic/diagnostic biomarker assays for patients with Lyme disease and PTLDS.

Children's National

Roberta L. DeBiasi, M.D., M.S., is Chief of the Division of Pediatric Diseases and Co-Director of the Congenital Zika Program at Children’s National Hospital. She holds appointments as tenured Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at George Washington University School of Medicine & Health Sciences as well as Principal Investigator in the Center for Translational Research at Children’s National Research Institute. Dr. DeBiasi’s research expertise includes basic science as well as clinical/translational research. She serves as Principal Investigator for research and clinical trials focusing on severe and emerging viral infections affecting pregnant women, neonates, immunocompromised hosts, and normal children. She is Co- Director of the Congenital Zika Program at Children's National which includes research protocols in the US and Colombia focused on prenatal imaging, testing, genetics and virologic aspects of congenital Zika infection. She leads the Children's National Ebola response and is Co-PI for federal funding to support Ebola preparedness. In addition, Dr. DeBiasi’s research portfolio includes a study evaluating the burden of pediatric Lyme disease, as well as long-term outcomes of Lyme infection in children. She is also involved in emergency investigational new drug (IND) acquisition of agents for treatment of severe viral myocarditis, encephalitis, and malaria. She is site PI for a PCORI- funded multicenter clinical trial evaluating optimal management of refractory Kawasaki Disease.

NIAID

Adriana Marques, M.D., is the Chief of the Lyme Disease Studies Unit, Laboratory of Clinical Immunology & Microbiology at the NIAID.

Protocol Title: Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study

Status: Active, not recruiting.

Project contact person: Saira Huq, [email protected]

The protocol is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population, including coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C), and characterize the immune response associated with these clinical presentations. Participants aged 21 years and younger with laboratory confirmed history of symptomatic or asymptomatic SARS-CoV-2 infection will visit the study sites for clinical and research evaluations and sample collection at schedules dependent on time since infection. Participants enrolled within 12 weeks after acute infection or positive test will be part of the “recovery group” and will attend study visits at baseline, every 3 months for the first 6 months, and subsequently every 6 months for a total of 3 years. Participants enrolled more than 12 weeks after acute infection or positive test will be in the “convalescent group” and will attend study visits at baseline and subsequently every 6 months for a total of 3 years.

Individuals (aged ≤21 years) without a diagnosis of SARS-CoV-2 infection or current symptoms suggestive of COVID-19 will serve as a control group and will attend visits for evaluations and sample collection at baseline and every 12 months for a total of 3 years. This protocol will establish a cohort of pediatric patients recovered from SARS CoV-2 infection and a biorepository for evaluation of the potential roles of host genetics, immune response, and other possible factors influencing long-term outcomes.

Children's National

Roberta L. DeBiasi, M.D., M.S.

NIAID

Gina Montealegre, M.D.

Protocol Title: Natural History Study of Pediatric-Onset Neuro-Immune Conditions with Discovery of Dysregulated Molecular And Genetic Pathways (NI-MAP)

Status: Recruiting.

Project contact person: Stephanie Norman, [email protected]

A natural history protocol for the evaluation of patients with genetically defined or undifferentiated pediatric diseases characterized by inflammation of the central nervous system using advanced genetics and immunophenotyping is currently being developed. Affected participants will be clinically evaluated and provide biological samples for research. Leftover samples from clinical procedures may also be used for research. Genotyping, HLA typing and immunophenotyping will be performed free of charge. Follow-up visit may be scheduled on the basis of clinical status, with the aim of molecularly characterizing biologic samples including CSF in both active and quiescent states. Unaffected biological parents will provide biological samples to be used as controls.

Children's National

Elizabeth Wells, M.D., is a graduate of Harvard University and the George Washington University School of Medicine and Health Sciences. She holds a master’s in Health Science from the NIH/Duke Clinical Research Training Program. Dr. Wells completed her pediatrics and neurology training at Children’s National Hospital and has been on staff as a pediatric neurologist within the Brain Tumor Institute and the Division of Neurology for the past 10 years.

In addition to her work in neuro-oncology at Children’s National, Dr. Wells also developed the multidisciplinary program in pediatric neuro-immunology. She serves on numerous national committees and receives national and international referrals for children with neuro-inflammatory disorders. She is a principal investigator for translational research studies and serves in a leadership role for the Clinical and Translational Science Institute at Children's National and the District of Columbia Intellectual and Developmental Disabilities Research Center. Dr. Wells has been director of Inpatient Neurology and the Neuroscience medical unit director since 2015 and was elected president of the medical staff in July 2020. In her role as vice president, Dr. Wells focuses on the programmatic development of the Center including work on quality and safety, medical informatics, diversity and inclusion and patient experience.

Ilana Kahn, M.D., is the Clinical Director of Neuroimmunology and the Director of the Pediatric Multiple Sclerosis Options at Children's National Hospital.

NIAID

Raphaela T. Goldbach-Mansky, M.D., M.H.S., received her medical degree from the University Witten-Herdecke, Germany, in 1990 and completed a combined residency in internal medicine and pediatrics at Case Western Reserve University, Metro Health Medical Center. She completed her rheumatology fellowship training at NIAMS in 1999 and served as a staff clinician at NIAMS through 2008. Dr. Goldbach-Mansky is chief of the NIAID Translational Autoinflammatory Disease Studies (TADS) Unit. She leads the NIAID autoinflammatory disease clinic and has built a translational research program focusing on clinical and translational studies in children with early-onset autoinflammatory diseases. Together with Dr. Daniel Kastner (NHGRI) she founded the Translational Autoinflammatory Research Initiative (TARI) at NIH to improve research in patients with rare autoinflammatory diseases.

Dr. Goldbach-Mansky's research focus is on applying a systematic approach to the clinical and immunological study of autoinflammatory diseases. Her group uses targeted interventions to understand the role of specific inflammatory pathways in the pathogenesis of autoinflammatory diseases.

Bibi Bielekova, M.D., received an M.D. in 1993 from Comenius University in Bratislava, Slovakia. After a medical internship at SUNY Downstate Medical Center in Brooklyn and a neurology residency at Boston University, she did a 3-year postdoctoral research fellowship at the NINDS Neuroimmunology Branch (NIB). She remained at NIB for an additional 5 years as a staff physician, focusing on development of novel therapies for MS. In 2005, she became associate professor of neurology with tenure and director of the Waddell Center for MS at University of Cincinnati. In 2008, she moved back to NINDS as an investigator. In 2018, Dr. Bielekova transferred as a senior investigator to NIAID. Her laboratory is studying mechanisms of immunoregulation and immune-mediated CNS tissue injury in MS and other neuroimmunological diseases with a long-term goal of developing effective therapies. In addition, Dr. Bielekova is a principal investigator on several innovative protocols including adaptively designed Phase I/II clinical trials.

One of the overarching goals of the CNH-NIAID partnership is to provide joint training opportunities for investigators studying and caring for children with infectious, immunologic, and allergic diseases. To date, 24 exceptional fellows have matched and been placed into the training programs. In 2020, a formal career mentorship program and a protocol writing workshop with program officers from the NIH Division of Allergy, Immunology, and Transplantation (DAIT) was initiated to better prepare fellows for careers in academic medicine.

Children's National

Suzanne Kochis, M.D., is the site director of the National Institute of Allergy and Infectious Diseases allergy and immunology fellowship program. She completed pediatric allergy immunology fellowship training at Johns Hopkins University. She obtained her M.D. from Jefferson Medical College of Thomas Jefferson University and then completed pediatric residency at Johns Hopkins, where she also served as Chief Resident. Her research at Hopkins focused on parental understanding of pediatric asthma control and outcomes for asthma, as well as a quality improvement project assessing adrenal insufficiency in patients with eosinophilic esophagitis on swallowed topical steroids. She now specializes in food allergies.

Dr. Kochis was the recipient of the American Academy of Pediatrics (AAP) Section on Allergy and Immunology (SOAI) Outstanding Abstract Award in 2017. She completed a Certificate in Quality, Patient Safety and Outcomes Research at the Johns Hopkins Bloomberg School of Public Health.

Nada Harik, M.D., is an attending physician in the Division of Infectious Diseases at Children's National Hospital in Washington, D.C and an Associate Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences.

Dr. Harik is the director of the Pediatric Infectious Diseases Fellowship Program at Children's National. She also serves as the clinical consultant for the Infection Control Program. Her main research and clinical interests are Staphylococcus aureus epidemiology and pathogenesis, osteomyelitis/septic arthritis, infections in children with cystic fibrosis, infection prevention, tick-borne infections, medical student/resident/fellow education and pediatric tuberculosis. Dr. Harik is an active member of the Pediatric Infectious Diseases Society.

NIAID

Paneez Khoury, M.D., M.H.Sc., F.A.A.A.A.I., is an associate research physician at NIAID. She has been involved in translational research in eosinophilic disorders since joining the Human Eosinophil Section in 2012.She received her M.D. from University of Illinois College of Medicine in Chicago. She completed an internal medicine residency at the Ohio State University followed by a fellowship in allergy and clinical immunology at NIH. She also holds a master’s of health sciences from Duke University. She is board certified in internal medicine and allergy/immunology and is a fellow of the American Academy of Allergy, Asthma and Immunology (AAAAI).

At NIH, she serves as the chair of the Scientific Review Committee of the Laboratory of Parasitic Diseases. She sits on the graduate medical education (GME) committee, including the policy subcommittee, and is a member of the staff clinician council. Her external committee activities include involvement in the food allergy and eosinophilic disorders committee, the program directors assembly, and the leadership institute of AAAAI . She serves on the board of the International Eosinophil Society (IES) and is the social media chair for the society.

Catherine Bollard, M.D., M.B.Ch.B., received her medical degree at the University of Otago in Dunedin, New Zealand. She is board certified both in pediatrics and hematology. She worked in New Zealand and London, England, before moving to Houston, Texas, in 2000 where she was a Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine (BCM). In August 2013, she was recruited to Washington, DC, to join Children’s National Hospital and George Washington University. She is currently the Bosworth Chair for Cancer Biology, Director of the Center for Cancer and Immunology Research, and Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) at Children’s National Hospital. She is a Professor of Pediatrics and of Microbiology, Immunology, and Tropical Medicine at George Washington University and the Associate Center Director for Translational Research and Innovation at the GW Cancer Center. Dr. Bollard is a member of the American Society for Clinical Investigation, is a past president of the International Society for Cellular Therapy, and the current President of the Foundation for the Accreditation of Cellular Therapy. She was a member of the Cellular, Tissues, and Gene Therapies Advisory Committee of the FDA from 2015 to 2019 and, in 2019, became a member of the Frederick National Laboratory Advisory Committee for the NIH and an ad hoc member of the Pediatric Oncologic Drugs Advisory Committee for the FDA. She was an associate editor for the journal Blood from 2014-2021 and is currently Editor in Chief of Blood Advances. She has >200 peer reviewed publications and has been independently NIH funded for over 15 years. Her bench and translational research focuses on improving outcomes for patients after transplant and on the development of novel cell therapies for cancer and virus-associated diseases.

H. Clifford Lane, M.D., serves as the National Institute of Allergy and Infectious Diseases' (NIAID) Deputy Director for Clinical Research and Special Projects. Dr. Lane's responsibilities include directing the activities of the Division of Clinical Research, which supports both intramural and extramural research involving human volunteers

Jeffrey Dome, M.D., Ph.D., is Senior Vice President of the Center for Cancer and Blood Disorders and Chief of the Division of Oncology at Children’s National Hospital in Washington, D.C. He also is Professor of Pediatrics at the George Washington University School of Medicine & Health Sciences and the Thomas Willson and Lenore Williams McKnew Professor of Pediatric Oncology. Dr. Dome received his M.D. degree from the University of Pennsylvania School of Medicine and his Ph.D. degree in Medicine from Erasmus University in Rotterdam. He completed a residency in Pediatrics at Yale-New Haven Hospital and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins Hospital. After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National Hospital in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee, which oversees clinical research on kidney tumors at more than 200 children’s hospitals around the world, for more than 10 years. Dr. Dome is the Continental President of North America for the International Society of Paediatric Oncology (SIOP). He is a member of the Hematology/Oncology Sub board of the American Board of Pediatrics and serves on numerous medical advisory boards for cancer foundations. He has authored more than 150 articles, books and chapters on pediatric cancer.

Pamela Guerrerio, M.D., Ph.D., graduated with a B.S. degree in biology from the University of Iowa and entered the Medical Scientist Training Program at Johns Hopkins University, where she completed medical school and a Ph.D. in human genetics. She also did her residency in pediatrics and fellowship in allergy and immunology at Johns Hopkins, and subsequently joined the faculty. In 2014, Dr. Guerrerio was recruited to the NIAID intramural research program as Chief of the Food Allergy Research Unit. She received tenure in 2019 and was named Chief of the Laboratory of Allergic Diseases in 2020. Dr. Guerrerio was the recipient of the ARTrust Faculty Development Award from the American Academy of Asthma, Allergy and Immunology in 2011. She received the Presidential Early Career Award for Scientists and Engineers, the National Science Foundation’s highest honor for science and engineering professionals in the early stages of their independent research career, in 2017.

Pamela S. Hinds, R.N., Ph.D., F.A.A.N., is the Director of the Department of Nursing Science, Professional Practice, and Quality, the William and Joanne Conway Endowed Chair in Nursing Research, and the Research Integrity Officer at Children's National Health System in Washington, D.C., and a Professor of Pediatrics at the George Washington University, School of Medicine and Health Sciences in Washington, D. C. She is an adjunct professor for the University of Pennsylvania, School of Nursing, Johns Hopkins University, School of Nursing, the University of Maryland, College of Nursing, and the Fudan University of Shanghai, China. For more than three decades, Dr. Hinds has created and led research related to the pediatric cancer experience, quality of life, fatigue and altered sleep during the treatment of pediatric cancers, and end-of-life communication and decision making. She has served on the Institute of Medicine (IOM) committee on end-of-life and palliative care for children in America (2003) and the National Quality Forum panel on palliative and end-of-life care in America, the Institute of Medicine (IOM) committee on Dying in America (2014) and is currently serving on the National Academies of Sciences, Engineering and Medicine Roundtable on Quality Care for People with Serious Illness (2016-2022), and the NCI Moonshot Tolerability Steering Committee (2019-present). Dr. Hinds is an Oncology Nursing Society Distinguished Nurse Researcher and the Association of Pediatric Oncology and Hematology Distinguished Nurse Researcher and is the Editor-in-Chief for the journal, CANCER NURSING: An International Cancer Journal and the open access journal, Cancer Care Research Online. She is the 2020 recipient of the HPNA Distinguished Nurse Researcher Award in Palliative Care and the 2020 Nightingale Award from the American Nurses Association and the Washington Post.

Gina Montealegre, M.D., is a physician scientist within the Division of Clinical Research, NIAID. She is a pediatric rheumatologist with a master's degree in Clinical Research. Dr. Montealegre has an extensive background in the development, execution and oversight of clinical trials in rare autoinflammatory diseases. Previously, she worked as a director of the Clinical Trials Unit at the Translational Autoinflammatory Disease Section at NIAID.

Luigi D. Notarangelo, M.D., received his medical degree from the University of Pavia, Italy. After completing training in pediatrics, subspecialty training in allergy/immunology, and human genetics at the University of Pavia and a postdoctoral internship with David Nelson, M.D., at the Metabolism Branch, National Cancer Institute, he was appointed associate professor and subsequently full professor of pediatrics at the University of Brescia, Italy, where he chaired the department of pediatrics between 2000 and 2006. In Nov. 2006, he joined the division of immunology at Boston Children’s Hospital, Harvard Medical School, as professor of pediatrics. In Oct. 2016, he joined the Laboratory of Host Defenses.

Dr. Notarangelo is a leader in the study of the molecular and cellular mechanisms of human primary immune deficiencies and in the treatment of these disorders. He has served as president of the European Society for Immune Deficiencies and of the Clinical Immunology Society. He has received numerous national and international awards.

David Wessel, M.D., is executive vice president, chief medical officer, physician-in-chief and the Ikaria Distinguished professor of Critical Care Medicine at Children's National Hospital. He is also professor of anesthesiology, critical care medicine and pediatrics at the George Washington University.

Dr. Wessel is internationally known for his pioneering work in caring for infants with heart disease. An experienced scientist and clinical researcher with more than 100 peer-reviewed publications, Dr. Wessel has designed and executed seminal studies in cardiac critical care and pulmonary hypertension; developed new therapies for perioperative care of the newborn with congenital heart disease and novel treatments of pulmonary hypertension; and studied neurologic outcomes relevant to perioperative care of newborns with congenital heart disease. He is a principal investigator and member of the steering committee for the Collaborative Pediatric Critical Care Research Network sponsored by the National Institutes of Health.

Stephanie Norman, M.P.H., joined the Children's National-NIAID partnership in July 2019 as the Clinical Research Coordinator. She has a Master's degree in Public Health from New York University. Prior to working at Children's National Hospital, she was a Clinical Research Coordinator in Maternal Fetal Medicine at Mount Sinai Hospital in New York City. AS the coordinator for the partnership, she works on regulatory submissions, data entry, recruitment and enrollment as well as other tasks associated with daily protocol activity.

Christine Peng, B.S.N, R.N., is the Research Nurse for the Children's National-NIAID partnership. Seh received her B.S. degree in Behavioral and Community Health from the University of Maryland, College Park, and B.S. in Nursing from University of Maryland, Baltimore. Christine's roles within the partnership include providing education and support for the clinical research studies and functioning as a resource for the Principal Investigators, patient/family, and community.

Infectious Disease Program: Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study

Saira Huq, M.P.H., is the Project Manager for the Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study. She has a Master of Public Health degree from the University of Pennsylvania and is a Fulbright Scholar. Prior to joining Children’s National, she helped evaluate federally funded public health programs and clinical trials at NORC at the University of Chicago and Westat. As project manager she coordinates study activities, monitors study progress, reports to the study sponsor, and helps ensure that project activities are completed on time, on budget, and within scope.

Lauren Arrigoni, C.P.N.P., R.N., is the pediatric nurse practitioner (NP) for the Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study with the Children's National-NIAID partnership. Her previous roles include pediatric heart transplant NP and Pediatric ICU nurse in NYC. At the height of the COVID-19 Pandemic in NYC in 2020, she was redeployed as a bedside nurse for the pediatric COVID-19 Unit and followed discharged COVID-19 pediatric patients as a part of the cardiology team.

She is completing her Doctor of Nursing Practice at the University of Pennsylvania. She obtained her BSN from the University of Pennsylvania as a Hillman scholar. While working full-time in the PICU, she graduated as a Pediatric Nurse Practitioner from NYU where she was given the Rising Star Award. She also volunteers as a camp nurse at the Double H Ranch, which is a camp for children with serious and chronic illnesses, founded by Paul Newman. She has volunteered with MakerNurse, a group supporting nurse innovations and served as a guest of Doctor Radio on SiriusXM. Lauren’s roles within the study include conducting study visits, assessing study test results, and enrolling participants for the study.

Mallory Barrix, M.P.H., C.H.E.S., joined the Children’s National-NIAID partnership in June 2021 as a Clinical Research Coordinator on the Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study. She has a Bachelor of Science in Human Development and Family Studies from the University of Wisconsin- Madison as well as a Master of Public Health degree from Emory University. In addition, she is also a Certified Health Education Specialist. As a Coordinator for the Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study, she handles regulatory submissions, patient recruitment and enrollment, and study visit organization among other tasks aimed at helping the study run smoothly.

Maureen Edu began working as a clinical research coordinator for the Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up Study in January 2022. She assists with enrollment, recruitment, regulatory submission, data collection/entry, and other daily operations of the clinical study. She obtained her B.S. in Biology from Randolph College. She formerly worked as a research coordinator for the Center for Prevention and Early Intervention at the Johns Hopkins Bloomberg School of Public Health.

6th Annual Children's National Hospital - NIAID Symposium

Promoting Child Health: From Environmental Challenges to Pandemic

April 27 - 28, 2023 | Children's National Research and Innovation Campus | 7144 13th Pl NW, Washington, DC 20012 

This annual symposium celebrates the partnership between Children’s National Hospital and the National Institute of Allergy and Infectious Diseases (NIAID). Established in 2017, the Children's National - NIAID partnership focuses on advancing the health of children with allergic, immunologic, and infectious diseases through collaborative research and education.

The event was held on Thursday, April 27 and Friday, April 28, 2023 at the Children’s National Research and Innovation Campus in DC. Together with our co-host, the Pediatric Pandemic Network (PPN), we will focus on Promoting Child Health: From Environmental Challenges to Pandemic.

The Pediatric Pandemic Network is a network of 10 children’s hospitals that serve as regional hubs for improving care for all children, their families, and communities in pandemics, disasters and every day. The PPN works with regional and national programs, academic institutions, community organizations, and individual experts to share pediatric-related information, educational resources, and best practices. In 2023, the priority focus areas for PPN activities include infectious disease/disease outbreaks, mental and behavioral health, healthcare emergency management, and health equity and community engagement.

Funding for this event has been provided by Children's National Research Institute, Center for Cancer and Immunology, and Center for Translational Research.

ABSTRACTS

• Scott Call
  Social Needs Screening in Critically-Ill Pediatric Patients with Asthma
• Ilana Kahn
  Initial Disease Severity Predicts Executive Functioning in Children with Anti-NMDA Receptor Encephalitis (NMDARE)
• Alexandra B. Kornbluh
  Cerebrospinal Fluid Eosinophils in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
• Olufunke Y. Martin
  The Evolution of the COVID-19 Pandemic in Pediatric Patients with Sickle Cell Disease: From Alpha to Omicron
• Chase D. McCann
  Phenotypic and Functional Impacts of Successive Antigen Stimulation on T cells: Implications for Clinical Manufacturing of TAA-T cell Products
• Maryam A. Pasdar
  Utilizing mRNA as a Source of Antigens for the Expansion of Virus-Specific T cells
• Shilpa J. Patel
  
  • Implementation of a Social Needs Screening Tool Across Multiple Settings for Children with Asthma
    
  • Automated Wheeze Detection in Children Using Data-Efficient Deep Learning Models
    
  • Spatial Analysis of Housing Problems and Asthma Control Among Children with Asthma in an Urban Environment
• Kazuhiro Sabet
  Increased Proliferation and Specificity of Tumor Associated Antigen Specific T-cells Using Checkpoint Inhibitor During Stimulation
• Jillian P. Smith
  Immune Activation by Antigen-specific T Cells Elicited in Patients Receiving Standard Therapy for Pediatric Solid Tumors
• Lani Tran
  Zika Infection Dysregulates Autophagy in Neural Stem Cells
• Meagan E. Williams
  United States Neurodevelopmental Outcomes of Zika Virus-Exposed Preschoolers

SYMPOSIUM RECORDING

• Day 1, Thursday, April 27, 2023 | View video recordings > 

• Day 2, Friday, April 28, 2023 | View video recordings >

AGENDA

THURSDAY, APRIL 27, 2023 | Environmental Challenges to Child Health

• Welcome: H. Clifford Lane, M.D.
• 12 - 12:30 p.m.: Keynote Presentation – "Tropical Medicine Vaccine Sciences to Catalyze Global Child Health" – Maria Elena Bottazzi, Ph.D., F.A.S.T.M.H.
• 12:30 - 2:30 p.m.: Session 1: Environmental Factors and Impact on Allergy – Moderator Hemant Sharma, M.D.
• 12:30 - 12:55 p.m.: “Evaluating Air Pollution as a Driver of Atopic Dermatitis" –Ian A. Myles, M.D., M.P.H.
• 12:55 - 1:20 p.m.: "Environmental Factors Contributing to the Food Allergy Epidemic" –Ruchi S. Gupta, M.D., M.P.H.
• 1:20 - 1:45 p.m.: "Childhood Asthma and Urban Environmental Exposures: Challenges and Possible Solutions" –Will Sheehan, M.D.
• 1:45 - 2:10 p.m.: Roundtable Q&A – With Erin Malawer from Allergy Strong
• 2:10 - 2:20 p.m.: Abstract Presentation: "ROSAH: A New Dominantly Inherited Disease Causing Autoinflammation and Progressive Blindness" – Christina Kozycki, M.D., M.P.H. (NHGRI/NIH)
• 2:20 - 2:30 p.m.: Abstract Presentation: "The Intersection Between Asthma Morbidity and Healthy Housing" Creation of an Interactive Health Housing Map for the District of Columbia" – Shilpa Patel, M.D., M.P.H. (Children's National Hospital)
• 2:30 - 3 p.m.: Break
• 3 - 5 p.m.: Session 2: Environmental Impact on Infectious Diseases Moderator: – Roberta L. DeBiasi, M.D., M.S.
• 3 - 3:35 p.m.: “Using a One Health Approach to Address the Planet’s Most Wicked Problems – Linked Health Risks Resulting From the Climate Crisis and Emerging Infectious Diseases” – Jonna Mazet, D.V.M., M.P.V.M., Ph.D. Q&A
• 3:35 - 4:10 p.m.: "Syndemic Perspective on Prevention and Response: How the National Mpox Response Activated Close Friends and New Partners" – Demetre C. Daskalakis, M.D., M.P.H. Q&A
• 4:10 - 4:40 p.m.: "Flooding in Pakistan, Disease Outbreaks, and Climate Justice" –Eugene Richardson, M.D., Ph.D. Q&A
• 4:40 - 4:50 p.m.: Abstract Presentation: "SARS-CoV-2 mRNA Vaccination Induces B cell Immunity in the Tonsils and Adenoids of Children" – Kalpana Manthiram, M.D., M.S.C.I. (NIAID)
• 4:50 - 5 p.m.: Abstract Presentation: "Temporal Trends of Blood Glucose in Children with Cerebral Malaria" – Meredith Sherman (Children's National Hospital)
• 5 p.m.: Reception

FRIDAY, APRIL 28, 2023| Pandemic Preparedness

• Welcome: Larry K. Kociolek, M.D., M.S.C.I., F.S.H.E.A., F.P.I.D.S.
• 9 - 9:30 a.m.: Keynote Presentation – "Pediatric Pandemics, Public Health Emergencies and Disasters: A Need for Capacity, Coordination and Science Across the Disaster Continuum" – Cinnamon Dixon, D.O., M.P.H.
• 9:30 a.m. - 12 p.m.: Session 1: Pandemic Policy – Moderator: Charles Macias, M.D., M.P.H.
• 9:30 - 9:35 a.m.: "Overview of the History of Developing the Pediatric Pandemic Network" – Mark L. Batshaw, M.D. Q&A
• 9:35 - 10 a.m.: "The HRSA Pediatric Pandemic Network: Preparing for the Next Disaster" –Joelle Simpson, M.D. Q&A
• 10 - 10:30 a.m.: "Pediatric Pandemic Network Preparedness and Responsiveness with a Community Engagement and a Health Equity Lens" – Tamera Coyne-Beasley, M.D., M.P.H., and Ariann Nassel, M.A. Q&A
• 10:30 - 11 a.m.: "Looking Forward: Addressing the Mental Health Crisis in Children and Adolescents" – Lee S. Beers, M.D. Q&A
• 11 - 11:30 a.m.: “Lessons Learned From the 2022 Pediatric Viral Respiratory Surge: The Intersections of Infectious Disease and Pediatric Emergency Management” – Christopher Newton, M.D., F,A.C.S., F.A.A.P. Q&A
• 11:30 am - 12 p.m.: Panel Discussion: Building Pediatric Capacity Solutions – Charles Macias, Joelle Simpson, Tamera Coyne-Beasley, Lee S. Beers, Christopher Newton, and journalist Sheryl Gay Stolberg, B.A., of New York Times
• Closing: Larry K. Kociolek, M.D., M.S.C.I., F.S.H.E.A., F.P.I.D.S.

This agenda may be subject to change. Please check back for updates or subscribe to the CTSI-CN newsletter to receive the latest information.

Questions? Contact us at [email protected].

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Society of Virginia (MSV) through the joint providership of Inova Office of Continuing Medical Education and Children's National Medical Center. The Inova Office Continuing Medical Education is accredited by the Medical Society of Virginia to provide continuing education for physicians.

Credit Designation:
The Inova Office of Continuing Medical Education designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 7.5 credits in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

Inova Health System’s Office of Continuing Medical Education adheres to ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, program directors, and planners are required to disclose all relevant financial relationships with ineligible entities as defined by ACCME.

Catherine Bollard, M.D., M.B.Ch.B., planner for this educational event, has honorarium relationship with Mana Therapeutics, Catamaran Bio, Cabaletta Bio; receipt of intellectual property rights relationship with Mana Therapeutics and Catamaran Bio; ownership relationship with Mana Therapeutics, Catamaran Bio, Cabaletta Bio; consulting relationship with Sobi, Pfizer, BMS, Cellectar. All relevant financial relationships listed for this individual has been mitigated.

Maria Elena Bottazzi, Ph.D., faculty for this educational event, has royalty relationship with Biological E BioFarma. All relevant financial relationships listed for this individual has been mitigated.

Tamera Coyne Beasley, M.D., M.P.H., faculty for this educational event, has consulting relationship with Pfizer, Moderna, Sanofi Pasteur. All relevant financial relationships listed for this individual has been mitigated.

Ruchi Gupta, M.D., faculty for this educational event, has contracted research relationship with Novartis; consulting relationship with Genentech, Novartis, Aimmune LLC, Allergenis LLC; ownership relationship with Yobee Care, Inc. All relevant financial relationships listed for this individual has been mitigated.

Larry Kociolek, M.D. faculty for this educational event, has contracted research relationship with Merck. All relevant financial relationships listed for this individual has been mitigated.

4th Annual Symposium (Virtual): June 3-4, 2021 | Agenda > | Recordings >

This annual symposium celebrates the partnership between Children’s National Hospital (CNH) and the National Institute of Allergy and Infectious Diseases (NIAID). Established in 2017, the CNH-NIAID partnership focuses on advancing the health of children with allergic, immunologic, and infectious diseases through collaborative research and education.

In 2021, the Symposium was held on Thursday, June 3rd and Friday, June 4th as a virtual event that highlighted research on COVID-19 and multisystem inflammatory syndrome in children (MIS-C), and the intersectionality of COVID-19, allergy, and immunology on the pediatric population. Keynote speaker pediatric neurologist and 73rd Governor of The Commonwealth of Virginia, Ralph Northam, spoke on the COVID-19 pandemic and strategies to reintroduce children into schools and sports.